PainNCT07909590
A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning
An observational study of Pain, run by HALEON at 1 site in Singapore.
Trial summary
The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pain
- What is being tested?
- Paracetamol
- Type of treatment
- Pill or oral medicine
- How many people
- 2,100 participants
- Where
- 1 siteSingapore
- Study dates
- Nov 2026to Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Residents of Australia, Malaysia, Colombia, Kenya who have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month and have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
Who may be able to join
- Residents of Australia, Malaysia, Colombia, Kenya.
- Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month.
- Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
- Self-reported healthy individuals.
- Able to provide informed consent.
- The specific Panadol/Dolex variant for each country as applicable.
Who cannot join
- Participants who experience headaches that occur 15 or more days per month.
- Participants with migraine.
- Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD [cannabidiol]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month.
- Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used.
- Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used.
- Participants affiliated with Sponsor or Contract Research Organization (CRO).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Multi-country, Retrospective, Real World Observational Study Evaluating the Impact of an Analgesic Product on Quality-of-Life and Daily Functioning
The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning.
Read the detailed description
This is a multi-country, real-world, observational, cross-sectional survey study. The target population for this survey study comprises individuals who have used Panadol/Dolex for the relief of more than or equal to (>=)1 headache episode in the past 1 month. Eligible participants will be directed to complete an online survey comprising of a series of questions designed to gather data relevant to the research objectives. The study population will be comprised of approximately 2,100 participants across Australia, Malaysia, Colombia, and Kenya.
- Conditions
- Pain
- Being tested
- Paracetamol
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ParacetamolDrug
Paracetamol 500 milligram (mg) taken orally.
| Study group | Role | What they receive |
|---|---|---|
| Panadol/Dolex Tablet | Participants who have taken Panadol/Dolex for at least 1 headache episode in the past 1 month. Receives: Drug: Paracetamol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Intensity Before Using Panadol/Dolex
Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome.
Measured: Within the past 1 month from time of participation
Perceived Relief From Panadol/Dolex Use
Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex.
Measured: Within the past 1 month from time of participation
QoL Assessment After Using Panadol/Dolex Post Headache Episode
Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life.
Measured: Within the past 1 month from time of participation
Secondary outcomes (8)
Frequency of Panadol/Dolex Use
Thinking about the recent headache episode, participants will be asked to mention the frequency of product use from 1 time a day to 4 times a day.
Measured: Within the past 1 month from time of participation
Timepoint of Panadol/Dolex Use
Participants will answer a single question related to timepoint of product use- 'Thinking about the same headache episode which you used Panadol for relief in the past one month, what did you first do to relieve the pain?' Participants will choose one of the given options.
Measured: Within the past 1 month from time of participation
Product Satisfaction
Thinking about the experience of using Panadol, participants will rate their overall satisfaction on a scale 1 to 5, where 1= Absolutely dissatisfied and 5= Completely satisfied.
Measured: Within the past 1 month from time of participation
Headache Management Behaviors
Participants will answer a single question related to headache management approaches they used before- 'Thinking about similar headaches you experienced before this episode, what did you do to relieve your headache in the past?' Participants will select one or more descriptive options provided.
Measured: Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Trust in The Product
Participants will answer a single question related to trust in the product- 'How much do you trust the product to provide fast headache pain relief?' Participants will choose one of the given options.
Measured: Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Value For Money
Thinking about experience of using the product, participants will be asked to rate the product's value for money on a scale 1 to 5, where 1= Poor value for money and 5= Excellent value for money.
Measured: Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Use Again
Participants will answer a single question related to continued purchase- 'How likely would you choose Panadol again for your next headache episode?'. Participants will choose one of the given options.
Measured: Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Recommend Other Consumers
Participants will answer a single question related to likelihood to recommend others- How likely would you recommend Panadol to other consumers experiencing headache pain? Participants will choose one of the given options.
Measured: Within the past 1 month from time of participation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study startNov 2026 (estimated)
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PainStudies of the same condition, open and under way.
- More trials run by HALEONThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 2,100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- HALEON
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07909590
- Sponsor's protocol ID
- 400384
- Status last verified
- Oct 2026
- First submitted
- 16 Oct 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-country, Retrospective, Real World Observational Study Evaluating the Impact of an Analgesic Product on Quality-of-Life and Daily Functioning
- ClinicalTrials.gov ID
- NCT07909590
- Acronym / sponsor ID
- 400384
- Conditions
- Pain
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,100 participants (estimated)
- Lead sponsor
- HALEONIndustry (pharma, biotech, devices)
- Study start
- Nov 2026 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning.
Detailed description
This is a multi-country, real-world, observational, cross-sectional survey study. The target population for this survey study comprises individuals who have used Panadol/Dolex for the relief of more than or equal to (>=)1 headache episode in the past 1 month. Eligible participants will be directed to complete an online survey comprising of a series of questions designed to gather data relevant to the research objectives. The study population will be comprised of approximately 2,100 participants across Australia, Malaysia, Colombia, and Kenya.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Panadol/Dolex Tablet | – | Drug: ParacetamolParticipants who have taken Panadol/Dolex for at least 1 headache episode in the past 1 month. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Residents of Australia, Malaysia, Colombia, Kenya who have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month and have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
Key inclusion criteria (6 listed)
- Residents of Australia, Malaysia, Colombia, Kenya.
- Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month.
- Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
- Self-reported healthy individuals.
- Able to provide informed consent.
Key exclusion criteria (6 listed)
- Participants who experience headaches that occur 15 or more days per month.
- Participants with migraine.
- Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD [cannabidiol]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month.
- Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used.
- Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ParacetamolParacetamol 500 milligram (mg) taken orally. | Drug | Panadol/Dolex Tablet |
Primary outcome
Pain Intensity Before Using Panadol/Dolex
Time frame: Within the past 1 month from time of participation
Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome.
Perceived Relief From Panadol/Dolex Use
Time frame: Within the past 1 month from time of participation
Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex.
QoL Assessment After Using Panadol/Dolex Post Headache Episode
Time frame: Within the past 1 month from time of participation
Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life.
8 secondary outcomes
Frequency of Panadol/Dolex Use
Time frame: Within the past 1 month from time of participation
Timepoint of Panadol/Dolex Use
Time frame: Within the past 1 month from time of participation
Product Satisfaction
Time frame: Within the past 1 month from time of participation
Headache Management Behaviors
Time frame: Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Trust in The Product
Time frame: Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Value For Money
Time frame: Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Use Again
Time frame: Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Recommend Other Consumers
Time frame: Within the past 1 month from time of participation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: Yes. Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
Related trials for Pain
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pain, run by HALEON at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Haleon Response Center (+441932 95 95 00, ww.clinical-trial-register@haleon.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Intensity Before Using Panadol/Dolex (time frame: Within the past 1 month from time of participation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026; AzTrials last refreshed its copy on 7 Nov 2026.